April 2020
· 3 min read
When access to your supplier’s facilities is limited or not permitted, how can you assure yourself of the quality standards in operation to provide continuity of supply of medicinal products, while meeting regulatory requirements and protecting the patient?
Using our network of international GMP experts, e-rooms and videoconferencing, NSF has developed a four-step approach to allow for remote and virtual GMP auditing which helps you to unlock supply chains and meet cGMP needs in clinical trial supply or routine commercial operations. This hybrid risk-based approach will help provide interim or conditional approval of facilities during periods of uncertainty or governmental restrictions.
Our approach can be applied to manufacturers of raw materials, GMP components, drug substances and drug products for key services including packaging, QC laboratories, warehousing, distribution and pharmacovigilance along with outsourced activities such as technical support, engineering contractors and QC release/stability testing.
Risk assessment of the operation to determine if a remote audit is feasible and justifiable to enable interim approval of your supplier, CMO or partner. Use the risk-based assessment checklist below for guidance.
Example Key Areas
Remote review of the pharma quality system by expert evaluation of the supplier’s key policies and procedures against internationally recognized quality and cGMP expectations.
Example Key Areas
Remote review and video conferencing session with subject matter experts to evaluate the evidence of implementation of the key policies and procedures.
Example Key Areas
After steps 2 and 3, the NSF expert will prepare a detailed written report of findings and recommendations with an aim of allowing interim approval where justified and warranted.
Where observations have been raised, the NSF expert will review the responses, CAPA plans and effectiveness checks to ensure they are appropriate.
Delivery of an on-site audit, to complete the formal GMP assessment. This can be an abbreviated review, given the comprehensive nature of steps 2 and 3.
Example Key Areas
Background Information | Information Required |
---|---|
Site Location |
|
Key Contact |
|
Site Assessment | Information Required |
---|---|
Regulatory Oversight |
|
Licenses/Registrations |
|
Inspection History |
|
Recalls |
|
Company Profile |
|
Site Activities |
|
Size of Location |
|
Cross-Contamination Risk |
|
Product Assessment | Information Required |
---|---|
Nature of Product/Material – Dose Forms |
|
Stage of Development for Product |
|